PERSONALIZED FERTILITY-PRESERVING MANAGEMENT OF OVARIAN ENDOMETRIOMAS: INTEGRATING SURGERY, HORMONAL THERAPY, OVARIAN RESERVE, AND ASSISTED REPRODUCTION

Authors

Keywords:

ovarian endometrioma; endometriosis; fertility preservation; ovarian reserve; anti-Müllerian hormone; dienogest; cystectomy; ablation; IVF; oocyte cryopreservation.

Abstract

Ovarian endometriomas represent a major therapeutic challenge in reproductive-age women because both the disease itself and its treatment may compromise ovarian reserve and future fertility. Traditional management has focused predominantly on surgical removal of the cyst; however, contemporary reproductive medicine increasingly emphasizes preservation of functional ovarian tissue and avoidance of unnecessary or repeated ovarian interventions.

Objective

To evaluate current medical, surgical, and reproductive strategies for ovarian endometriomas and to propose a personalized fertility-preserving approach integrating ovarian reserve, hormonal therapy, surgical technique, recurrence prevention, assisted reproductive technology, and fertility preservation.

Materials and Methods

A structured narrative review was conducted using PubMed/MEDLINE and current European Society of Human Reproduction and Embryology recommendations. Priority was given to international clinical guidelines, systematic reviews, meta-analyses, randomized controlled trials, and high-quality comparative studies published predominantly between 2022 and September 2026. Outcomes of interest included serum anti-Müllerian hormone (AMH), antral follicle count (AFC), endometrioma size, recurrence, oocyte yield, clinical pregnancy, and live birth.

Results

Cystectomy provides effective recurrence control but is associated with postoperative deterioration of ovarian reserve, particularly after bilateral and repeated surgery. Ablative techniques result in a smaller decline in AMH but may carry a greater recurrence risk. Hormonal therapies, including dienogest, combined hormonal contraceptives, GnRH agonists, and selected other regimens, can significantly reduce endometrioma dimensions and control symptoms. Their fertility-preserving effect is predominantly indirect through recurrence prevention and avoidance of repeated surgery. Ethanol sclerotherapy represents a potential ovarian-sparing option in selected patients. Routine surgery before IVF/ICSI does not improve live-birth rates and may reduce AMH and the number of retrieved oocytes. Oocyte or embryo cryopreservation should be considered before potentially damaging ovarian interventions in selected high-risk women.

Conclusion

The management of ovarian endometriomas should shift from a lesion-centred model toward individualized reproductive management. Age, AMH, AFC, laterality, previous ovarian surgery, symptoms, recurrence risk, reproductive timing, and anticipated need for assisted reproduction should guide treatment selection. Preservation of functional ovarian tissue and future reproductive potential should be considered major therapeutic endpoints.

 

References

1.Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L, et al. ESHRE guideline: endometriosis. Hum Reprod Open. 2022;2022(2). doi:10.1093/hropen/hoac009.

2.Younis JS, Taylor HS. The impact of ovarian endometrioma and endometriotic cystectomy on anti-Müllerian hormone, and antral follicle count: a contemporary critical appraisal of systematic reviews. Front Endocrinol (Lausanne). 2024;15:1397279. doi:10.3389/fendo.2024.1397279.

3.Paik H, Jee BC. Impact of ablation versus cystectomy for endometrioma on ovarian reserve, recurrence, and pregnancy: an updated meta-analysis. Reprod Sci. 2024;31(7):1924–1935. doi:10.1007/s43032-024-01512-z.

4.Eberle A, Nguyen DB, Papillon Smith J, Mansour FW, Krishnamurthy S, Zakhari A. Medical management of ovarian endometriomas: a systematic review and meta-analysis. Obstet Gynecol. 2024;143(1):53–66. doi:10.1097/AOG.0000000000005444.

5.Thiel PS, Donders F, Kobylianskii A, Maheux-Lacroix S, Matelski J, Walsh C, Murji A. The effect of hormonal treatment on ovarian endometriomas: a systematic review and meta-analysis. J Minim Invasive Gynecol. 2024;31(4):273–279. doi:10.1016/j.jmig.2024.01.002.

6.Veth VB, Keukens A, Reijs A, Bongers MY, Mijatovic V, Coppus SFPJ, Maas JWM. Recurrence after surgery for endometrioma: a systematic review and meta-analyses. Fertil Steril. 2024;122(6):1079–1093. doi:10.1016/j.fertnstert.2024.07.033.

7.Lavadia CMM, Jeong HG, Ryu KJ, Park H. Ovarian reserve and IVF outcomes after ethanol ovarian sclerotherapy in women with endometrioma: a systematic review and meta-analysis. Reprod Biomed Online. 2025;51(1):104840. doi:10.1016/j.rbmo.2025.104840.

8.Nicolì P, Viganò P, Saccone G, Di Naro E, Vimercati A, Cicinelli E, Vitagliano A. Oocyte cryopreservation for patients with endometriosis: where are we now? A systematic review. Reprod Biomed Online. 2025;51(1):104839. doi:10.1016/j.rbmo.2025.104839.

9.Riemma G, García-Velasco JA, Abrão MS, et al. IVF/ICSI or surgery as first approach for the treatment of infertility associated with ovarian and deep infiltrating endometriosis? A systematic review and meta-analysis. Reprod Biomed Online. 2026;52(2):105178.

10.Miller KAR, Servidoni ACP, Dos Santos PL, Surmann H, da Silva DBP, Andres MP, et al. Optimal laparoscopic surgical technique for preserving fertility and ovarian reserve in patients with endometrioma: a systematic review and Bayesian network meta-analysis of randomized controlled trials. J Minim Invasive Gynecol. 2026;33(7):868–878. doi:10.1016/j.jmig.2026.01.039.

11.Téoule J, Bundschu K, Hancke K. Individualized fertility preservation counselling for women with endometriosis—a systematic review. Wien Med Wochenschr. 2026. doi:10.1007/s10354-026-01151-w.

12.Richard E, Morin J, Murji A, Lemyre M, Laberge PY, Maheux-Lacroix S. Effect of postoperative hormonal suppression on fertility in patients with endometriosis after conservative surgery: a systematic review and meta-analysis. Obstet Gynecol. 2022;139(6):1169–1179. doi:10.1097/AOG.0000000000004811.

Published

2026-09-25